However, in an exploratory analysis of a phase II study of bevacizumab and erlotinib in platinum-resistant ovarian cancer, a prognostic association between tumor VEGF-A expression and disease progression (PD) was identified (p = 0.03); for every 100-unit increase in the VEGF-A score, there was a 3.7-fold increase in the odds of progression (95% CI: 1.1–16.6) [38]. This evidence concerns the gene VEGFA and ovarian carcinoma.